AUA: Atenolol linked to drop in low-, intermediate-risk prostate cancer

AUA: atenolol linked to drop in low-, intermediate-risk prostate cancer

(HealthDay)—Atenolol is associated with a reduction in incident intermediate- and low-risk prostate cancer (PCa), according to a study presented at the annual meeting of the American Urological Association, held from May 3 to 6 in Chicago.

Ali Zahalka, M.D., Ph.D., from the Albert Einstein College of Medicine and Montefiore Medical Center in Bronx, New York, and colleagues conducted a retrospective review of men who underwent initial prostate biopsy for any clinical indication between 2006 and 2016 to examine the correlation between use of oral beta-blockers and incident PCa. Data were included for 4,182 men who underwent initial prostate biopsy during the study period.

Based on preceding prescription refill history, the researchers found that 669 men (16 percent) were included in the beta-blocker cohort; 350 of these men had benign pathology and 319 had PCa. Of all men with PCa on biopsy, 8.1, 25.0, 4.0, and 16.0 percent had high-, intermediate-, low-, and very low-risk PCa. After adjustment for age, , body mass index, , , and race, the beta-blocker atenolol displayed a significant protective effect on incident low-risk and intermediate-risk PCa (odds ratios, 0.55 and 0.11, respectively).

"Our results, combined with recent results from preclinical models of PCa, provide preliminary support for further research into the use of atenolol as a potential protective pharmacologic agent against de novo PCa or PCa disease progression," the authors write.


Explore further

Could common heart meds lower prostate cancer risk?

More information: Abstract
More Information

Copyright © 2019 HealthDay. All rights reserved.

Citation: AUA: Atenolol linked to drop in low-, intermediate-risk prostate cancer (2019, May 6) retrieved 17 June 2019 from https://medicalxpress.com/news/2019-05-aua-atenolol-linked-low-intermediate-risk.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more